Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
152
-
Total 13F shares, excl. options
-
36.4M
-
Shares change
-
-567K
-
Total reported value, excl. options
-
$1.78B
-
Value change
-
-$45.3M
-
Put/Call ratio
-
1.14
-
Number of buys
-
76
-
Number of sells
-
-75
-
Price
-
$48.91
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2016
182 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2016.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 152 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.4M shares
of 96M outstanding shares and own 37.89% of the company stock.
Largest 10 shareholders include FMR LLC (5.85M shares), Capital Research Global Investors (4.78M shares), WELLINGTON MANAGEMENT GROUP LLP (4.19M shares), VANGUARD GROUP INC (2.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.59M shares), BlackRock Fund Advisors (1.39M shares), WELLS FARGO & COMPANY/MN (1.35M shares), STATE STREET CORP (1.27M shares), BlackRock Institutional Trust Company, N.A. (879K shares), and COLUMBIA WANGER ASSET MANAGEMENT LLC (863K shares).
This table shows the top 152 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.